Patients experience immune-related adverse events such as colitis, hypothyroidism, hepatitis, hypophysitis, hyperthyroidism, and pneumonitis, which are significantly escalated when combined with anti-CTLA-4 and anti-PD-1 therapy [122]. This evidence concerns the gene CTLA4 and Hepatitis.